Loading...
•
Sep 30, 2021
Ashland Q4 2021 Earnings Report
Ashland's Q4 2021 financial results were announced, showing sales up by twelve percent and net income significantly increased compared to the prior-year quarter.
Key Takeaways
Ashland reported strong Q4 2021 results with sales increasing by 12% to $591 million, driven by strong demand, enhanced pricing, and the Schülke & Mayr acquisition. Net income rose to $43 million, and adjusted EBITDA reached $149 million. The company also issued its fiscal year 2022 outlook, expecting further growth.
Sales increased by 12% year-over-year to $591 million, driven by strong demand and strategic acquisitions.
Net income significantly improved to $43 million, compared to $5 million in the prior-year quarter.
Adjusted EBITDA rose to $149 million, up from $131 million in the prior-year quarter.
The company provided a fiscal year 2022 outlook, anticipating continued growth and improved financial performance.
Ashland
Ashland
Ashland Revenue by Segment
Revenue by Segment
Life Sciences Revenue
CapyFin.comPersonal Care Revenue
CapyFin.comSpecialty Additives Revenue
CapyFin.comIntermediates Revenue
CapyFin.com Forward Guidance
For fiscal year 2022, Ashland expects sales in the range of $2.25 billion to $2.35 billion and adjusted EBITDA in the range of $550 million to $570 million.
Positive Outlook
- Improving demand across all businesses.
- Teams are working to implement pricing actions to offset cost inflation.
- Focus on consistent organic growth.
- Improving margins.
- Enhanced free cash flow generation.
Challenges Ahead
- Meaningful cost inflation for raw materials.
- Meaningful cost inflation for freight.
- Meaningful cost inflation for energy.
- Persistent supply-chain challenges.
- Persistence of the global pandemic is still impacting consumer behavior.
Revenue & Expenses
Visualization of income flow from segment revenue to net income